Midazolam injection - Alfresa Pharma

Drug Profile

Midazolam injection - Alfresa Pharma

Alternative Names: AF 0901; Midafresa

Latest Information Update: 26 May 2017

Price : $50

At a glance

  • Originator Alfresa Pharma Corporation
  • Class Benzodiazepines; Hypnosedatives; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Epilepsy

Most Recent Events

  • 26 May 2017 Alfresa Pharma completes a phase III trial for Epilepsy (In neonates, In infant, In children, In adolescents) in Japan before May 2017 (JapicCTI-173586)
  • 01 May 2017 Alfresa Pharma initiates enrolment in a phase III trial for Epilepsy (In neonates, In infant, In children, In adolescents) in Japan before May 2017 (JapicCTI-173586)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top